NeutraSiga Therapeutics

NeutraSiga Therapeutics, Inc

A Biotech Company transforming Human Proteins into Therapeutic Compounds.

Human protein platform

NeutraSiga
Mission

NeutraSiga’s mission is to protect and nurture preterm newborns with biosynthetic compounds made with human cells.

Underdevelopment of the neonatal immune system predisposes infants to inflammatory disorders e.g., Necrotizing Enterocolitis (NEC)

Alterations early in life influence disease outcomes later in life, and human proteins found in human milk can improve early life outcomes.

Human milk is a drug

Human Immune Milk™ therapeutics

NeutraSiga is developing Human Immune Milk™ therapeutics derived from donor milk, recombinant biotechnology and cell cultured human milk.

NeutraSiga is advancing pre-clinical studies for Human Immune Milk™ Therapeutics to improve anti-microbial, anti-inflammatory and growth acceleration outcomes in preterm infants with human proteins.

Corporate and Press Contact

available from 10:00 – 17:00

Address 630 Pena Dr., Davis, CA 95618

Email info@neutrasiga.com

v. 919-450-7226